Literature DB >> 16623766

Microarray-based understanding of normal and malignant plasma cells.

John De Vos1, Dirk Hose, Thierry Rème, Karin Tarte, Jérôme Moreaux, Karéne Mahtouk, Michel Jourdan, Hartmut Goldschmidt, Jean-François Rossi, Friedrich W Cremer, Bernard Klein.   

Abstract

Plasma cells (PCs) develop from B lymphocytes following stimulation by antigen and express a genetic program aimed at the synthesis of immunoglobulins. This program includes the induction of genes coding for transcription factors such as PRDM1, X-box-binding protein 1 and BHLHB3, cell-surface molecules such as CD138/syndecan-1, and for the unfolded protein response. We review how the microarray technology has recently contributed to the understanding of the biology of this rare but essential cell population and its transformation into premalignant and malignant PCs.

Entities:  

Mesh:

Year:  2006        PMID: 16623766      PMCID: PMC1955683          DOI: 10.1111/j.0105-2896.2006.00362.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  117 in total

1.  Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family.

Authors:  Q Lu; G Lemke
Journal:  Science       Date:  2001-07-13       Impact factor: 47.728

2.  Plasma cell differentiation requires the transcription factor XBP-1.

Authors:  A M Reimold; N N Iwakoshi; J Manis; P Vallabhajosyula; E Szomolanyi-Tsuda; E M Gravallese; D Friend; M J Grusby; F Alt; L H Glimcher
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

3.  In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma.

Authors:  M Portier; G Rajzbaum; X G Zhang; M Attal; C Rusalen; J Wijdenes; P Mannoni; D Maraninchi; M Piechaczyk; R Bataille
Journal:  Eur J Immunol       Date:  1991-07       Impact factor: 5.532

4.  Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function.

Authors:  H W Mittrücker; T Matsuyama; A Grossman; T M Kündig; J Potter; A Shahinian; A Wakeham; B Patterson; P S Ohashi; T W Mak
Journal:  Science       Date:  1997-01-24       Impact factor: 47.728

5.  Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

Authors:  P L Bergsagel; M Chesi; E Nardini; L A Brents; S L Kirby; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

6.  Failure of B-cell differentiation in mice lacking the transcription factor EBF.

Authors:  H Lin; R Grosschedl
Journal:  Nature       Date:  1995-07-20       Impact factor: 49.962

7.  Impaired immune and acute-phase responses in interleukin-6-deficient mice.

Authors:  M Kopf; H Baumann; G Freer; M Freudenberg; M Lamers; T Kishimoto; R Zinkernagel; H Bluethmann; G Köhler
Journal:  Nature       Date:  1994-03-24       Impact factor: 49.962

8.  Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation.

Authors:  M H Bakkus; C Heirman; I Van Riet; B Van Camp; K Thielemans
Journal:  Blood       Date:  1992-11-01       Impact factor: 22.113

9.  Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.

Authors:  H Uchiyama; B A Barut; A F Mohrbacher; D Chauhan; K C Anderson
Journal:  Blood       Date:  1993-12-15       Impact factor: 22.113

10.  A coordinated change in chemokine responsiveness guides plasma cell movements.

Authors:  D C Hargreaves; P L Hyman; T T Lu; V N Ngo; A Bidgol; G Suzuki; Y R Zou; D R Littman; J G Cyster
Journal:  J Exp Med       Date:  2001-07-02       Impact factor: 14.307

View more
  24 in total

1.  Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

Authors:  Jerome Moreaux; Dirk Hose; Alboukadel Kassambara; Thierry Reme; Philippe Moine; Guilhem Requirand; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

2.  Influence of Plasma Cell Niche Factors on the Recruitment and Maintenance of IRF4hi Plasma Cells and Plasmablasts in Vaccinated, Simian Immunodeficiency Virus-Infected Rhesus Macaques with Low and High Viremia.

Authors:  Julia M Shaw; Leia K Miller-Novak; Venkatramanan Mohanram; Katherine McKinnon; Thorsten Demberg; Diego A Vargas-Inchaustegui; David Venzon; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

3.  Regulatory and Helper Follicular T Cells and Antibody Avidity to Simian Immunodeficiency Virus Glycoprotein 120.

Authors:  Matthew J Blackburn; Ma Zhong-Min; Francesca Caccuri; Katherine McKinnon; Luca Schifanella; Yongjun Guan; Giacomo Gorini; David Venzon; Claudio Fenizia; Nicolò Binello; Shari N Gordon; Christopher J Miller; Genoveffa Franchini; Monica Vaccari
Journal:  J Immunol       Date:  2015-08-21       Impact factor: 5.422

4.  Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.

Authors:  Monica Vaccari; Shari N Gordon; Slim Fourati; Luca Schifanella; Namal P M Liyanage; Mark Cameron; Brandon F Keele; Xiaoying Shen; Georgia D Tomaras; Erik Billings; Mangala Rao; Amy W Chung; Karen G Dowell; Chris Bailey-Kellogg; Eric P Brown; Margaret E Ackerman; Diego A Vargas-Inchaustegui; Stephen Whitney; Melvin N Doster; Nicolo Binello; Poonam Pegu; David C Montefiori; Kathryn Foulds; David S Quinn; Mitzi Donaldson; Frank Liang; Karin Loré; Mario Roederer; Richard A Koup; Adrian McDermott; Zhong-Min Ma; Christopher J Miller; Tran B Phan; Donald N Forthal; Matthew Blackburn; Francesca Caccuri; Massimiliano Bissa; Guido Ferrari; Vaniambadi Kalyanaraman; Maria G Ferrari; DeVon Thompson; Marjorie Robert-Guroff; Silvia Ratto-Kim; Jerome H Kim; Nelson L Michael; Sanjay Phogat; Susan W Barnett; Jim Tartaglia; David Venzon; Donald M Stablein; Galit Alter; Rafick-Pierre Sekaly; Genoveffa Franchini
Journal:  Nat Med       Date:  2016-05-30       Impact factor: 53.440

5.  A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Authors:  Jérôme Moreaux; Bernard Klein; Régis Bataille; Géraldine Descamps; Sophie Maïga; Dirk Hose; Hartmut Goldschmidt; Anna Jauch; Thierry Rème; Michel Jourdan; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

6.  Phenotypes and distribution of mucosal memory B-cell populations in the SIV/SHIV rhesus macaque model.

Authors:  Thorsten Demberg; Venkatramanan Mohanram; David Venzon; Marjorie Robert-Guroff
Journal:  Clin Immunol       Date:  2014-05-09       Impact factor: 3.969

7.  Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Authors:  Karène Mahtouk; Jérôme Moreaux; Dirk Hose; Thierry Rème; Tobias Meissner; Michel Jourdan; Jean François Rossi; Steven T Pals; Hartmut Goldschmidt; Bernard Klein
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

8.  Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Authors:  A Seckinger; T Meissner; J Moreaux; H Goldschmidt; G M Fuhler; A Benner; M Hundemer; T Rème; J D Shaughnessy; B Barlogie; U Bertsch; J Hillengass; A D Ho; V Pantesco; A Jauch; J De Vos; J F Rossi; T Möhler; B Klein; D Hose
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

Review 9.  Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.

Authors:  Karène Mahtouk; Dirk Hose; John De Vos; Jérôme Moreaux; Michel Jourdan; Jean François Rossi; Thierry Rème; Harmut Goldschmidt; Bernard Klein
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

10.  TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.

Authors:  Jérôme Moreaux; Dirk Hose; Michel Jourdan; Thierry Reme; Michael Hundemer; Marion Moos; Nicolas Robert; Philippe Moine; John De Vos; Hartmut Goldschmidt; Bernard Klein
Journal:  Haematologica       Date:  2007-06       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.